Collectively we have worked with over 480 life sciences companies assessing new technologies, performing due diligence, and providing strategic direction. With over $22M in direct investment decisions under our belt, we can not only identify winners from losers, but our intellectual capital can help you drive decisions.
Life science markets are converging, and delivery models are changing, making traditional pipeline planning obsolete. With over 75 years of combined cross vertical experience, we can navigate and anticipate shifting markets. Our cross vertical experience in therapeutics, medical devices, biotechnology, diagnostics, and healthcare IT provides insights to support decisions for new value propositions and business models.
Our proprietary analytic tools, like our IP Pyramid Analysis™ will de-risk decisions and provide a pathway for successful technology commercialization. Unique competitive landscaping and market mapping tools uncover pitfalls and provide clear direction for product acquisition, market disruption, and pipeline planning.
